
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
+12
Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Companys lead asset, Descartes-08, is a potential first-in-class mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis and Phase 2 development for systematic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Companys clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T. For more information, please visit www.cartesiantherapeutics.com
Immunotherapy,oncology,molecular biology,immunology,autoimmune diseases,myasthenia gravis,ards,cell therapy,lung disease,nets,cardiovascular disease,gene therapy,cancer research,multiple myeloma,sle,mrna,and car-t
Cartesian therapeutics operates in the Biotechnology research industry.
Cartesian therapeutics's revenue is 11m - 100m
Cartesian therapeutics has 51 - 200 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.